Asia-Pacific

In today's edition, A 'democratisation' expert says GPs will only get one chance to deliver; Blackstone reckons evergreen 'tests' are helpful for the industry; New Mountain wants to deepen its Korea ties.

After a surge in interest around the covid-19 pandemic, it has been a mixed picture for life sciences and biotech-focused PE fundraising and capital deployment.

The number of Asia-Pacific portfolio companies held for more than five years rose 18% in 2025, according to Bain & Co’s Asia-Pacific Private Equity Report 2026.

The Tokyo Stock Exchange is increasing minimum market capitalisation for companies listed in its Growth Market section to ¥10bn by 2030.

The number of GP stakes and GP M&A deals jumped 40% year-over-year, according to Campbell Lutyens’ latest GP M&A report.

The country has taken a larger share of Asia-Pacific's stilted private equity market over recent years.

Funding to AI-related start-ups spiked 75% to $203bn from 2024, with foundation model companies representing 40% of that globally and US companies dominating.

The firm reportedly paused a multi-asset CV involving this asset in 2023.

Short-term and increasingly passive public markets aren’t always the right fit for major transformations, particularly those being driven by trends such as decarbonisation and AI.

Do customisable models incorporating both public and private markets exposure represent the next step in the democratisation of alternatives?